Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MedicalCV's cardiac ablation system:

This article was originally published in Clinica

Executive Summary

MedicalCV has received US FDA 510(k) market clearance to use its surgical ablation system, AtriLaze, on cardiac tissue in surgery. The clearance marks the firm's shift from the mechanical heart valve market, where it had reported "significant losses on modest revenues", into the faster-growing atrial fibrillation (AF) sector. The Minneapolis, Minnesota company expects to start marketing AtriLaze via a direct US sales force in January 2005.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT060559

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel